Annexon (ANNX) announced the appointment of William “BJ” Jones to its board of directors. He currently serves as chief commercial officer of NewAmsterdam Pharma Company (NAMS).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment
- Annexon announces topline results from RWE study of ANX005 in GBS
- Annexon to present Phase 2 ARCHER DATA on ANX007
- Annexon Biosciences Reports Q3 Financial Results
- Annexon reports Q3 EPS (25c), consensus (27c)